2’-Deoxy-2’-azidonucleoside Analogues: Synthesis and Evaluation of Antitumor and Antimicrobial Activity

**Adam Mieczkowski1\*, Patrycja Wińska2, Marta Kaczmarek1,2, Magdalena Mroczkowska1,3, Damian Garbicz1, Tomasz Pilżys1, Michał Marcinkowski1, Jan Piwowarski1, Elżbieta Grzesiuk1**

1Institute of Biochemistry and Biophysics, Polish Academy of Sciences, Pawinskiego 5a, 02-106 Warsaw, Poland

2Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warsaw, Poland

3Department of Chemistry, University of Warsaw, Pasteura 1, 02-093 Warsaw, Poland

**\***Corresponding author, e-mail: amiecz@ibb.waw.pl

Received [Dates will be filled in by the Editorial office]

Abstract

A series of 10 pyrimidine nucleosides modified in 2’ position with azide or amine group was tested for their antibacterial, antifungal and cytotoxic activity. The cytotoxic effect was determined on three cancer (CCRF-CEM, MCF7, HeLa) and one normal (HEK293) cell lines, while antibacterial activity was evaluated on five bacterial strains. Among others, 2’-azido-2’-deoxycytidine and 2’-amino-2’-deoxycytidine exhibited the strongest antiproliferative activity at 200 μM concentration, decreasing the viability of CCRF-CEM cells to 33±1% and 36±2%, respectively. Newly synthesized 2’-amino-2’-deoxythymidine exhibited cytotoxic effect exclusively towards HeLa cancer cell line, but not towards the normal HEK293 cells. Also, investigated compounds did not exhibit any antibacterial nor antifungal activity at concentration of 40 mM. Obtained results suggest that the presence of cytosine base is desirable for the appearance of cytotoxic effect, while the structural variations of sugar ring play a minor role. Future modification of 2’-amino-2’-deoxythymidine could be a promising way to obtain more active anticancer substances.

**Keywords:** azidonucleosides, cytotoxicity, antifungal, antibacterial, CCRF-CEM, MCF7, HeLa HEK293 cell lines

Introduction

Nucleoside derivatives which possess azide group (Pathak 2002) focused great attention of medicinal chemists after discovery that 3’-azido-3’-deoxythymidine (Zidovudine, **1**, Scheme 1) could act as an efficient HIV reverse transcriptase inhibitor, and could be applied to treatment of acquired immune deficiency syndrome (AIDS) (Mitsuya et al. 1985) (Fig 1.). The utility and high potential of azide-modified nucleoside analogues was further supported by the discovery of 4’-azidocytidine (**2**, R1479), a relatively potent (IC50 = 320 nM) inhibitor of RNA synthesis mediated by NS5B, the RNA polymerase encoded by HCV (Smith et al. 2007). Earlier reports also revealed great potential of 2-azido-2’-deoxy-3-(β-D-arabinofuranosyl)cytosine (**3**, Cytarazid) against various human tumor cell lines (Bobek et al. 1978; Cheng et al. 1981; Matsuda et al. 1991) and HSV virus strains (Cheng et al. 1981).It was firstdesigned as cytidine deaminase-resistant analogue of the anticancer compound - 3-(β-D-arabinofuranosyl)cytosine (AraC).

In the pyrimidine 2’-azido-2’-deoxyribonucleoside series, only the unmodified 2’-azido-2’-deoxyuridine (**4**) and 2’-azido-2’-deoxycytidine (**5**) are vastly described in the literature, ignoring the remaining representatives of the class. Reported data are greatly focused on interactions of compounds **4** and **5** with different types of cellular enzymes. Because of the lack of 2’-hydroxy group, pyrimidine 2’-azido-2’-deoxynucleosides are recognized and phosphorylated to the appropriate monophosphates by human deoxyribonucleoside salvage enzymes, such as deoxycytidine kinase (dCK) (Iwata et al. 1979; Wanf et al 1998; Kierdaszuk et al 1998; Kierdaszuk et al 1999). The diphosphate of 2’-azido-2’-deoxycytidine (**5**) exhibits strong inhibition effect on ribonucleotide reductase, a pivotal enzyme involved in the DNA synthesis, which transforms ribonucleosides into their 2’-deoxyribonucleoside analogues (Akerblom 1985; Wnuk et al. 2002; Roy et al. 2004). Additionally, in its 5’-triphosphate form, it also inhibited the action of primase in a reconstructed E. *coli* enzyme system (Reichard et al. 1978). During investigation of structural requirements and determinants for nucleoside affinity to the proteins responsible for the nucleoside transport through cell membranes, 2’-azido-2’-deoxyuridine (**4**) exhibited rather high affinity to the human concentrative nucleoside transporters (hCNTs) (hCNT1 *K*i [μM] = 11.5 ± 0.5, hCNT3 *K*i [μM] = 33.3 ± 2.0, hCNT2 *K*i [μM] > 3000) (Zhang et al. 2003; Zhang et al. 2005) and human equilibrative nucleoside transporters (hENTs) (hENT1 *K*i [μM] = 13 ± 1, hENT1 *K*i [μM] = 169 ± 14) (Vickers et al. 2004), investigated in yeast expression system. 2’-Azido-2’-deoxyuridine (**4**) and 2’-azido-2’-deoxycytidine (**5**) were both tested in studies determining the effects of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase (UrdPase) from *Toxoplasma gondii* (el Kouni et al. 1996). While 2’-azido-2’-deoxycytidine (**5**) didn’t exhibit any significant binding activity, 2’-azido-2’-deoxyuridine (**4**) exhibited strong biding effect to this enzyme, with inhibitory potency of 82.1 ± 28.5 μM (3.42 times greater potency than the reference compound – β-D-uridine). Among the tested compounds, 2’-azido-2’-deoxycytidine (**5**) was also the most active one (IC50 = 0.05 ± 0.01 μM, SI = >2030 ± 1347) against a highly pathogenic avian H5N1 influenza A virus strain (Kumaki et al. 2011),Vietnam/1203/2004. Also, it inhibited polyoma virus DNA replication (Bjursel 1977; Bjursel 1978; Eliasson et al. 1981). In another report, this compound exhibited significant inhibitory effect against leukemic L1210 cell line, rather weak antiviral activity against vaccinia virus, and lack of significant activity against HSV (Herpes Simples Virus) and VSV (vesicular Stomatitis Virus) virus strains (de Clercq et al. 1980).

Although 2’-azido-2’-deoxycytidine (**5**) doesn’t exhibit any significant antiretroviral activity, because of its ribonucleotide reductase-inhibition activity, it could be used as a potentiator of anti-HIV drugs, such as AZT (Giacca et al. 1994; Giacca et al. 1996). Cytidine deaminase, an enzyme responsible for deactivation of cytidine-derived anticancer drugs, e.g. Cytarabine, by limiting their bioavailability and half–life time, is also strongly inhibited by azidonucleoside **5** (Cacciamani et al. 1991). Consequently, due to its cytidine deaminase-inhibition activity, compound **5** could extend bioavailability, half-life time and decrease therapeutic doses and side-effects of several anticancer drugs. Polynucleotides possessing 2’-azido-2’-deoxyuridine (**4**) were also investigated as possible interferon inducers (Torrence et al 1973; Torrence et al 1973).



**Fig 1.** Representative, medicinally-relevant pyrimidine azidonucleosides: **1** Zidovudine (anti-HIV), **2** R1479 (anti-HCV), **3** Cytarazid (anticancer, anti-HSV), **4** 2’-azido-2’-deoxyuridine, **5** 2’-azido-2’-deoxycytidine (antiviral, anticancer).

In our ongoing quest for the design and synthesis of new medicinally relevant nucleoside analogues and heterocyclic derivatives (Mieczkowski et al. 2015; Mieczkowski et al. 2016;Mieczkowski et al. 2016), we envisioned the possibility of synthesizing novel, 2’-azido modified pyrimidine nucleosides. Because of the lack of synthetic and biological data corresponding to the modified pyrimidine 2’-azido-2’-deoxyribonucleosides in literature, we decided to synthesize novel analogues of 2’-azido-2’-deoxyuridine (**4**) and 2’-azido-2’-deoxycytidine (**5**) and compare their biological activities against cancer lines, bacteria and fungi with parent compounds. For comparative studies and investigation of structure-activity relationships we also used three 2’-amino-2’-deoxy pyrimidine nucleoside analogues.

Experimental

Commercially available chemicals were of reagent grade purity and used as received. 2,2’-Anhydrouridine, 2,2’-anhydrothymidine (**12**), 2’-azido-2’-deoxycytidine (**3**), 2’-amino-2’-deoxyuridine (**15**), 2’-amino-2’-deoxycytidine (**16**) were purchased from Carbosynth (United Kingdom). The reactions were monitored by thin layer chromatography (TLC) analysis using silica gel plates (Kieselgel 60F254, E. Merck). Column chromatography was performed on Silica Gel 60M (0.040-0.063 mm, E. Merck). Melting points are uncorrected and were measured on a Kofler apparatus. The 1H and 13C NMR spectra were recorded at the Department of Chemistry, Warsaw University, using Varian Unity Plus spectrometer (500 MHz) and Bruker AVANCE III HD (300 MHz) spectrometer, in CDCl3 and DMSO-*d6*, with shift values in parts per million relative to SiMe4 as internal reference. The resonance assignments are based on peak integration, peak multiplicity and 2D correlation experiments. Multiplets were assigned as s (singlet), d (doublet), t (triplet), q (quartet), dd (doublet of doublet), dt (doublet of triplet), ddd (doublet of dublet of doublet), m (multiplet), and bs (broad singlet). High Resolution Mass spectra were performed by the Laboratory of Mass Spectrometry, Institute of Biochemistry and Biophysics PAS, on LTQ Orbitrap Velos, Thermo Scientific. The antibacterial and antifungal activity of compounds was assayed using standardized disc diffusion agar test. Disc diffusion method was carried out according to the standard method (Bauer et al. 1966). Clinically antimicrobial drugs: kanamycin and amphotericin B, were used as reference drugs and DMSO was used as a negative control. The results were recorded as the average diameter of growth inhibition zones, and for the reference drugs were minimum 20 mm of bacterial or fungal growth around the disks was inhibited. For the tested compounds there were no growth inhibition zones observed.

**2’-azido-5-bromo-2’-deoxy-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (7a)** 1.00 g (2.0 mmol, 1 eq.) of 2’-azido-2’-deoxy-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (**6**) was dissolved in the 50 ml of dichloromethane and 0.88 g (4.0 mmol, 2 eq.) of silver trifluoroacetate followed by addition of 0.31 ml (6.0 mmol, 3eq.) of bromine, and reaction mixture was stirred in RT for 18 hrs. The inorganic silver salts were separated by filtration through Celite, the organic phase was washed twice with saturated solution of sodium thiosulphate and once with brine. The organic phase was dried over the magnesium sulfate, volatiles were evaporated under the reduced pressure. The solid residue was purified by column chromatography on silica gel using toluene:ethyl acetate, 9:1 to 8:2. Yield 0.32 g (28%). Compound **7a** was obtained as white crystals, m.p.: 78.4-78.9°C.1H NMR (500 MHz, CDCl3): 8.96 (bs, 1H, NH), 7.99 (s, 1H, H6), 6.24 (d, 1H , 3*J*=7.0 Hz, 1H, H1’), 4.35 (dd, 3*J*=2.0, 5.0 Hz, 1H, H3’), 4.10 (q, 3*J*=2.0 Hz, 1H, H4’), 3.96 (dd, 3*J*=2.0 Hz, 2*J*=12.0 Hz, 1H, H5’b), 3.77 (dd, 3*J*=2.0 Hz, 3*J*=12.0 Hz, 1H, H5’a), 3.51 (dd, 3*J*=5.0, 7.0 Hz, 1H, H2’), 0.95 (s, 18H, 2 x *t*-BuSi), 0.19 (s, 3H, MeSi), 0.17 (s, 3H, MeSi), 0.16 (s, 3H, MeSi), 0.14 (s, 3H, MeSi); 13C NMR (125 MHz, CDCl3): 158.6, 149.5, 138.5, 97.7, 86.9, 85.8, 73.5, 65.6, 62.6, 26.1, 25.7, 18.5, 18.1, -4.7, -5,0, -5.2, -5.3. HRMS (ESI): *m/z* [M+H]+ calculated for C21H39BrN5O5Si2: 576.16676, found: 576.16672.

**2’-azido-2’-deoxy-5-iodo-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (7b)** 1.00 g (2.0 mmol, 1 eq.) of 2’-azido-2’-deoxy-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (**6**) was dissolved in the 50 ml of dichloromethane and 0.88 g (4.0 mmol, 2 eq.) of silver trifluoroacetate followed by addition of 1.52 g (6.0 mmol, 3eq.) of iodine and reaction mixture was stirred in RT for 18 hrs. The inorganic silver salts were separated by the filtration through Celite, the organic phase was washed twice with saturated solution of sodium thiosulphate and once with brine. The organic phase was dried over the magnesium sulfate, volatiles were evaporated under the reduced pressure. The solid residue was purified by column chromatography on silica gel using toluene:ethyl acetate, 9:1 then 8:2. Yield 0.96 g (72%). Compound **7b** was obtained as white crystals, m.p.: 150.0-150.3°C.1H NMR (500 MHz, CDCl3): 9.15 (s, 1H, NH), 8.00 (s, 1H, H6), 6.24 (d, 1H , 3*J*=7.5 Hz, 1H, H1’), 4.36 (dd, 3*J*=2.0, 5.0 Hz, 1H, H3’), 4.10 (q, 3*J*= 2.0 Hz, 1H, H4’), 3.93 (dd, 3*J*=2.0 Hz, 2*J*=11.5 Hz, 1H, H5’b), 3.76 (dd, 3*J* =2.0 Hz, 2*J* =11.5 Hz, 1H, H5’a), 3.49 (dd, 3*J* =5.0, 7.5 Hz, 1H, H2’), 0.96 (s, 9H, *t*-BuSi), 0.95 (s, 9H, *t*-BuSi), 0.19 (s, 3H, MeSi), 0.18 (s, 3H, MeSi), 0.17 (s, 3H, MeSi), 0.14 (s, 3H, MeSi); 13C NMR (125 MHz, CDCl3): 159.8, 150.0, 143.5, 87.0, 85.6, 73.7, 69.5, 65.4, 62.7, 26.3, 25.8, 18.6, 18.1, -4.7, -4.9, -5.1, -5.2. HRMS (ESI): *m/z* [M+H]+ calculated for C21H39IN5O5Si2: 624.15289, found: 624.15229.

**2’-azido*-*2’-deoxy-*O*4-(2,4,6-triisopropylbenzenesulphonyl)-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (9)** To the solution of 0.50 g (1.0 mmol, 1 eq.) of 2’-azido-2’-deoxy-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (**6**) dissolved in the 30 ml of dry dichloromethane, 0.91 g (3.0 mmol, 3 eq.) of TPSCl, 25 mg (0.2 mmol, 0.2 eq.) of DMAP and 0.41 ml of TEA were added, and reaction mixture was stirred in RT for 18 hrs. The obtained solution was then evaporated with silica gel and chromatographed using 100% toluene then toluene:ethyl acetate 9:1. Yield: 0.56 g (73%) of colourless oil.1H NMR (500 MHz, CDCl3): 8.48 (d, 1H, 3*J*=7.5 Hz, H6), 7.26 (s, 1H, HAr), 7.21 (s, 1H, HAr), 6.02 (d, 1H, 3*J*=7.5 Hz, H5), 5.76 (d, 1H , 3*J*=1.5 Hz, 1H, H1’), 4.31 (dd, 3*J*=5.0, 7.0 Hz, 1H, H3’), 4.25 (septet, 2H, 3*J*=7.0 Hz, 2 × *i*-Pr), 4.06 (m, 2H, H4’+H5’b), 3.93 (dd, 3*J*=1.5, 5.0 Hz, 1H, H2’), 3.76 (m, 1H, H5’a), 2.91 (septet, 1H, 3*J*=7.0 Hz, *i*-Pr), 1.33 (d, 6H, 3*J*=7.0 Hz, *i*-Pr), 1.27 (d, 6H, 3*J*=7.0 Hz, *i*-Pr), 1.26 (d, 6H, 3*J*=7.0 Hz, *i*-Pr), 0.94 (s, 9H, *t*-Busi), 0.91 (s, 9H, *t*-Busi), 0.13 (s, 3H, MeSi), 0.12 (s, 3H, MeSi), 0.11 (s, 3H, MeSi), 0.10 (s, 3H, MeSi); 13C NMR (125 MHz, CDCl3): 167.3, 154.6, 153.8, 151.2, 145.6, 130.6, 124.1, 95.0, 89.2, 83.9, 69.1, 66.6, 60.2, 34.3, 29.7, 26.0, 25.6, 24.7, 24.4, 23.5, 23.5, 18.4, 18.0, -4.4, -5.0, -5.3, -5.6. HRMS (ESI): *m/z* [M+H]+ calculated for C36H62N5O7SSi2: 764.39030, found: 764.38988.

**2’-azido*-*2’-deoxy-4-oxime-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (10)** The solution of 0.80 g of **9** (1.05 mmol, 1 eq.) dissolved in the 10 ml of THF was treated with 0.62 ml of 50% hydrazine solution in water (10.50 mmol, 10 eq.) and the reaction mixture was stirred in RT for the one hour. The volatiles were evaporated under the reduced pressure followed by co-evapotarion with 20 ml of toluene (three times). The oily residue was chromatographed on the silica gel using toluene:ethyl acetate 8:2. Yield: 0.43 g (80%) of colourless oil.1H NMR (500 MHz, CDCl3): 8.83 (bs, 1H, NH), 7.10 (d, 3*J*=8.5 Hz, 1H, H6), 6.11 (d, 1H , 3*J*=5.5 Hz, 1H, H1’), 5.65 (d, 3*J*=8.5 Hz, 1H, H5), 4.35 (dd, 3*J*=3.5, 5.5 Hz, 1H, H3’), 4.02 (m, 1H, H4’), 3.90 (dd, 3*J*=2.5 Hz, 2*J*=11.5 Hz, 1H, H5’b), 3.73 (dd, 3*J*=1.5 Hz, 2*J*=11.5 Hz, 1H, H5’a), 3.59 (t, 3*J*=5.5 Hz, 1H, H2’), 0.94 (s, 9H, *t*-BuSi), 0.92 (s, 9H, *t*-BuSi), 0.17 (s, 3H, MeSi), 0.13 (s, 3H, MeSi), 0.10 (s, 6H, 2xMeSi); 13C NMR (125 MHz, CDCl3): 149.4, 145.1, 129.9, 98.7, 85.6, 85.4, 72.7, 65.0, 62.3, 25.9, 25.7, 18.4, 18.1, -4.7, -5.0, -5.5, -5.6. HRMS (ESI): *m/z* [M+H]+ calculated for C21H41N6O5Si2: 513.26715, found: 513.26632.

**General procedure of the silyl group removal** 3’,5’-*O*-di(*t*-butyldimethylsilyl)nucleosides **7a-b** and **10** (1 eq) were dissolved in THF (10 ml per 1 mmol of nucleoside). Then, the TBAF hydrate (3 eq) was added and the reaction mixture was stirred in RT for 4 hours. After evaporation of solvent and co-evaporation with the toluene (20 ml, three times), the residue was dissolved in methanol, evaporated with silica gel and chromatographed using 5% methanol in chloroform.

**2’-azido-5-bromo-2’-deoxyuridine (8a)** yield: 93%, m.p.: 116.9-117.3°C,white crystals.1H NMR (300 MHz, DMSO-*d6*): 11.89 (s, 1H, NH), 8.44 (s, 1H, H6), 5.93 (d, 3*J* =5.7 Hz, 1H, OH3’), 5.77 (d, 3*J* =4.5 Hz, 1H, H1’), 5.36 (t, 3*J* =4.8 Hz, 1H, OH5’), 4.33 (q, 3*J*=5.7 Hz, 1H, H3’), 4.17 (dd, 3*J*=4.5, 5.7 Hz, 1H, H2’), 3.89 (dt, 3*J*=2.7, 5.7 Hz, 1H, H4’), 3.73 (ddd, 3*J*=2.7, 4.8 Hz, 2*J*=12.3 Hz, 1H, H5’b), 3.59 (ddd, 3*J*=2.7, 4.8 Hz, 2*J*=12.3 Hz, 1H, H5’a);13C NMR (125 MHz, DMSO-*d6*): 159.2, 149.7, 139.8, 96.0, 86.4, 84.9, 69.6, 65.2, 59.4.HRMS (ESI): *m/z* [M+H]+ calculated for C9H11BrN5O5: 347.99381, found: 347.99561.

**2’-azido-5-iodo-2’-deoxyuridine (8b)** yield: 64%, m.p.: 146.0-146.3°C, white crystals.1H NMR (500 MHz, DMSO-*d6*): 11.76 (s, 1H, NH), 8.45 (s, 1H, H6), 5.93 (d, 3*J* =5.5 Hz, 1H, OH3’), 5.77 (d, 3*J* =4.5 Hz, 1H, H1’), 5.34 (t, 3*J* =5.0 Hz, 1H, OH5’), 4.33 (q, 3*J*=5.5 Hz, 1H, H3’), 4.16 (dd, 3*J*=4.5, 5.5 Hz, 1H, H2’), 3.90 (ddd, 3*J*=2.5, 3.0, 5.5 Hz, 1H, H4’), 3.72 (ddd, 3*J*=3.0, 4.5 Hz, 2*J*=12.0 Hz, 1H, H5’b), 3.59 (ddd, 3*J*=2.5, 4.5 Hz, 2*J*=12.0 Hz, 1H, H5’a);13C NMR (125 MHz, DMSO-*d6*): 160.5, 150.1, 144.5, 86.3, 84.9, 79.2, 69.7, 69.6, 65.2, 59.5.HRMS (ESI): *m/z* [M+H]+ calculated for C9H11IN5O5: 395.97994, found: 395.98029.

**2’-azido*-*2’-deoxy-4-oxime-uridine (11)** yield: 55%, m.p.: 192.2-192.4°C, white crystals.1H NMR (500 MHz, DMSO-*d6*): 10.05 (s, 1H, OH), 9.66 (d, 4*J*(NH-H5)=2.0 Hz, 1H, NH), 7.03 (d, 3*J*=8.5 Hz, 1H, H6), 5.93 (m, 1H, OH3’+H1’), 5.61 (dd, 4*J*(NH-H5)=2.0 Hz, 3*J*=8.5 Hz, 1H, H5), 5.09 (t, *J*=5.0 Hz, 1H, OH5’), 4.25 (dt, 3*J*=3.5, 5.0 Hz, 1H, H3’), 3.88 (dd, 3*J*=5.0, 7.0 Hz, 1H, H2’), 3.85 (q, 3*J*=3.5 1H, H4’), 3.55 (m, 2H, H5’a+ H5’b); 13C NMR (125 MHz, DMSO-*d6*): 149.3, 143.1, 129.2, 99.1, 85.3, 84.3, 71.2, 63.2, 60.9.HRMS (ESI): *m/z* [M+H]+ calculated for C9H13N6O5: 285.09419, found: 285.09299.

**The synthesis of 2’-azido-5-chloro-2’-deoxyuridine (8c)** The solution of 0.38 g of **4** (0.68 mmol, 1 eq.) dissolved in the 5 ml of dry THF was treated with 0.1 ml of sulfuryl chloride and reaction mixture was stirred overnight in RT. The volatiles were evaporated under the reduced pressure, and oily residue was chromatographed on the silica gel using 5% methanol in chloroform. Yield: 85 mg (41%) of colorless oil. 1H NMR (300 MHz, DMSO-*d6*): 11.92 (s, 1H, NH), 8.36 (s, 1H, H6), 5.93 (d, 3*J* =5.4 Hz, 1H, OH3’), 5.77 (d, 3*J* =4.5 Hz, 1H, H1’), 5.36 (t, 3*J* =4.5 Hz, 1H, OH5’), 4.33 (q, 3*J*=5.4 Hz, 1H, H3’), 4.15 (dd, 3*J*=4.5, 5.4 Hz, 1H, H2’), 3.89 (dt, 3*J*=2.7, 5.4 Hz, 1H, H4’), 3.73 (ddd, 3*J*=2.7, 4.5 Hz, 2*J*=12.3 Hz, 1H, H5’b), 3.60 (ddd, 3*J*=2.7, 4.2 Hz, 2*J*=12.3 Hz, 1H, H5’a); 13C NMR (125 MHz, DMSO-*d6*): 159.1, 149.6, 137.4, 107.4, 86.5, 85.0, 69.6, 65.2, 59.5. HRMS (ESI): *m/z* [M+H]+ calculated for C9H11ClN5O5: 304.04432, found: 304.04433.

**2’-azido-2’-deoxy-5-methyluridine (13)** The solution of 3.00 g of 2,2’-anhydrothymidine (**12**, 12.49 mmol, 1 eq) dissolved in the 100 ml of dry DMF was treated with 0.58 g (22.48 mmol, 1.8 eq) of lithium fluoride, 2.98 ml of azidotrimetylsilane (22.48 mmol, 1.8 eq), and 3.37 ml of TMEDA (22.48 mmol, 1.8 eq), and reaction mixture was stirred 48 h in 110-115°C. The volatiles were evaporated under the reduced pressure and oily residue was chromatographed on the silica gel using 10% methanol in chloroform. Yield: 1.59 g (45%) of colorless oil. 1H NMR (500 MHz, DMSO-*d6*): 11.40 (s, 1H, NH), 7.72 (q, 4*J*(Me-H6)=1.0 Hz, 1H, H6), 5.95 (d, 3*J* =5.5 Hz, 1H, OH3’), 5.90 (d, 3*J* =5.5 Hz, 1H, H1’), 5.20 (t, 3*J* =5.0 Hz, 1H, OH5’), 4.31 (m, 1H, H3’), 4.04 (t, 3*J*=5.5 Hz, 1H, H2’), 3.89 (m, 1H, H4’), 3.68 (ddd, 3*J*=3.5, 5.0 Hz, 2*J*=12.0 Hz, 1H, H5’b), 3.58 (ddd, 3*J*=3.5, 5.0 Hz, 2*J*=12.0 Hz, 1H, H5’a), 1.78 (d, 4*J* (Me-H6) =1.0 Hz, 1H, Me). 13C NMR (125 MHz, DMSO-*d6*): 163.7, 150.5, 135.7, 109.7, 85.3, 85.2, 70.6, 64.3, 60.4, 12.3. HRMS (ESI): *m/z* [M+H]+ calculated for C10H14N5O5: 284.09895, found: 284.09914.

**2’-amino-2’-deoxy-5-methyluridine (14)** 1.00 g (3.53 mmol) of 2’-azido-2’-deoxy-5-methyluridine (**13**) was dissolved in 40 ml of isopropyl alcohol and 100 mg of 10% palladium on charcoal were added. The reaction vessel was connected to a balloon filled with hydrogen and the reaction mixture was stirred at room temperature for 20 h. The resultant solution was filtered through Celite and evaporated giving 772.0 mg (85%) of **14** as colorless oil. 1H NMR (500 MHz, DMSO-*d6*): 7.67 (q, 4*J*(Me-H6)=0.5 Hz, 1H, H6), 5.66 (d, 3*J* =8.0 Hz, 1H, H1’), 3.90 (dd, 3*J*=1.5, 5.5 Hz, 1H, H3’), 3.89 (dd, 3*J*=1.5, 3.5 Hz, 1H, H4’), 3.56 (m, 2H, H5’), 3.30 (dd, 3*J*=5.5, 8.0 Hz, 1H, H2’),1.78 (d, 4*J* (Me-H6)=0.5 Hz, 1H, Me). Acidic protons: NH, OH, NH2 not present in 1H-NMR spectra.13C NMR (125 MHz, DMSO-*d6*): 163.8, 152.2, 136.5, 109.4, 87.7, 85.9, 71.3, 61.7, 57.2, 12.3. HRMS (ESI): *m/z* [M+H]+ calculated for C10H16N3O5: 258.10845, found: 258.10874.

**Cell culture and treatment:** MCF7 adherent cells (human breast cancer cell line) were cultured in DMEM medium (Lonza) supplemented with 10% fetal bovine serum (Biowest), 2 mM L-glutamine, antibiotics (100 U/ml penicillin, 100 µg/mL streptomycin) and 10 µg/mL of human recombinant insulin (Sigma-Aldrich). CCRF-CEM suspension cells (human peripheral blood T lymphoblast cell line) were cultured in RPMI medium (Gibco) supplemented with 10% fetal bovine serum and antibiotics (100 U/mL penicillin, 100 µg/mL streptomycin). Cells were grown in 75 cm2 cell culture flasks (Sarstedt), in a humidified atmosphere of CO2/air (5/95%) at 37 °C. Cervical cancer cells HeLa, and human embryonic kidney cells HEK293 were cultured in DMEM medium (Life Technology) supplemented with 10% fetal bovine serum (Life Technology), 0,1% antibiotics (penicillin, streptomycin, Life Technology). Cells were grown in a humidified atmosphere of CO2/air (5/95%) at 37 °C.

**MTT-based cytotoxicity and alamarBlue® cell viability assay:** Before the treatment, MCF7 cells were trypsinized in 0.25% trypsin-EDTA solution (Sigma-Aldrich) and seeded into 96-well microplates at a density of 1.5 x 104 cells/well. Cells were treated with specific compounds dissolved in DMSO or DMSO (0.5%) at the corresponding concentrations, 18 h after plating (at 70% of confluency). CCRF-CEM were seeded at 104 cells/well and treated with tested compounds. MTT stock solution (Sigma-Aldrich) was added to each well to a final concentration of 0.3 mg/mL. After 2 h of incubation at 37 °C, water-insoluble dark blue formazan crystals were dissolved in DMSO (200 µL) (37°C/10 min incubation), and Sorensen’s glycine buffer (0.1 M glycine, 0.1 M NaCl, pH 10.5) was added (25 μL per well). Optical absorbance was measured at 570 nm using Synergy H4, BioTek microplate reader. All measurements were carried out in triplicate and the results are expressed in percentage of cell viability relative to control (cells without inhibitor in 0.5% DMSO). HeLa and HEK293 cells were seeded in 96-well microplates at a density of 7x103 cells/well. After 18 h, cells were treated with test compounds dissolved in DMSO at corresponding concentrations for 24 h. Then, 10% Alamar Blue (Invitrogen) was added according to the manufacturer’s protocol. After 4 h incubation, emission at 585 nm was measured with excitation at 570 nm, using a scanning multi-well spectrophotometer, DTX 880.

Results and discussion

Starting point of our synthesis was the 2’-azido-2’-deoxy-3’,5’-*O*-di(*t*-butyldimethylsilyl)uridine (**6**) prepared according to the reported procedure (Gai et al. 2010). Silyl protected nucleoside **6** was then bromidated in the C5 position using Br2/CF3COOAg system, which resulted in the formation of bromoderivative **7a** with 28% yield. In the similar manner, derivative **6** was iodinated in the C5 position with I2/CF3COOAg (Kobayasji et al. 1980), giving iododerivative **7b** in 72% (Scheme 1). Alternatively, iodine monochloride ICl could be used for the synthesis of **7b** (Gold et al. 1995). Silyl intermediates **7a-b** were then deprotected with the TBAF hydrate in THF to the final nucleosides **8a** and **8b** with 93% and 64% yield respectively. The treatment of protected nucleoside **6** with sulfuryl chloride in DCM resulted in the formation of 5-chloroderivative with concurrent cleavage of silyl groups. The deprotected 3-chloronucleoside **8c** was isolated as a sole product with 41% yield.  **Scheme 1.** Synthesis of 5-halogeno-2’-deoxy-2’-azidouridine derivatives **8a-c**

Silyl protected nucleoside **6** was also transformed into the *O*4-TPS derivative **9** with 73% yield using TPSCl, in the presence of triethylamine excess and catalytic amounts of 4-(dimethylamino)pyridine (Scheme 2) (Hari et al 2011). Obtained intermediate **9** was treated then with hydroxylamine solution in THF, what resulted in the formation of oxime derivative **10** with 80% yield, deprotected to the final product **11** with the TBAF hydrate in THF (55% yield).

 **Scheme 2.** Synthesis of 4-oximeuridine derivative **11**

2’-Azido-2’-deoxyuridine (**4**) was synthesized using a literature procedure (Kirschenheuterer al. 1994) and reported conditions were then applied to the synthesis of 2’-azido-2’-deoxy-5-methyluridine (2’-azidothymidine, **13**). The treatment of 2,2’-anhydrothymidine (**12**) with lithium fluoride and azidotrimethylsilane in DMF, in the presence of TMEDA at 110-115°C led to the opening of anhydro-bridge and formation of 2’-azidoderivative **13** with 45% yield (Scheme 3). The opening of anhydronucleoside **12** could be also performed with lithium azide/HMPA instead of azidotrimethylsilane (Pokrovskii et al. 2005). 2’-Azidothymidine (**13**) was then dissolved in the isopropyl alcohol and hydrogenated in the presence of catalytic amount of 5% palladium on activated charcoal, giving 2’-aminothymidine (**14**) with 85 % yield. The reduction of azide to the amine group could also be done with triphenylphosphine in ammonium hydroxide (Pokrovskii et al. 2005).




**Scheme 3.** Synthesis of 2’-azidothymidine (**13**) and 2’-aminothymidine (**14**)

In the initial experiments, the synthesized compounds **4**, **8a-c**, **11**, **13**, **14** and commercially available reference substances **5**, **15** and **16** were tested for their antiproliferative activity on MCF7 (human breast adenocarcinoma) and CCRF-CEM (T-cell lymphoblastic leukemia) cell lines (Table 1). The investigated compounds possessed substituent variations on sugar (N3 versus NH2 in C2’ position) and/or pyrimidine ring (H, Cl, Br, I in C5 position, C=O and C=N-OH in C4 position), giving an attractive pool for the investigation of structure-activity relationships. The most active compound in the 2’-azido-2’-deoxy series, the 2’-azido-2’-deoxycytidine (**5**), decreased cell viability at 200 μM concentration to 33±1% for CCRF-CEM cell line. The structural modifications of 2’-azido-2’-deoxycytidine (**5**) led to the *N*4-hydroxy-2’-azido-2’-deoxycytidine (**11**) (introduction of –OH group in *N*4 position of cytidine ring) and 2’-azido-2’-deoxyuridine (**4**) (exchange of cytosine into the uracil ring) - compounds deprived of antiproliferative activity. 5-chloro- (**8c**) 5-bromo- (**8a**), 5-iodo (**8b**) and 5-methylderivative (**13**) also didn’t exhibit any significant antiproliferative activity against both lines of cancer cells. In the 2-amino-2’-deoxy- series, 2’-amino-2’-deoxycytidine (**16**) showed the highest cytotoxic activity, decreasing cell viability at 200 μM concentration to 36±2% for CCRF-CEM, with an effect similar to the one observed for 2’-azido-2’-deoxycytidine (**5**). The exchange of azido group into the amino group in compound (**5**) had almost no influence on the cytotoxic effect on investigated cell lines. In contrast, uridine analogues of compound **16**: 2’-amino-2’-deoxuridine (**15**) and its 5-methyl derivative (**14**) didn’t decrease cell viability at 200 μM concentration.

**Table 1.** Antiproliferative activity against MCF7 and CCRF-CEM cell lines of 2’-amino and 2’-azidonucleoside analogues.

|  |  |  |
| --- | --- | --- |
| **Compound** | **Concentration 200 µM**  (Cell viability % ± SD, after 24 h incubation) | |
| MCF7 | CCRF-CEM |
| **4** | 101 ± 2 | 102 ± 5 |
| **5** | 82 ± 5 | 33 ± 1 |
| **8a** | 98 ± 3 | 101 ± 1 |
| **8b** | 100 ± 2 | 103 ± 5 |
| **8c** | 97 ± 4 | 99 ± 6 |
| **11** | 95 ± 3 | 92 ± 7 |
| **13** | 96 ± 3 | 95 ± 7 |
| **14** | 94 ± 2 | 101 ± 6 |
| **15** | 94 ± 2 | 70 ± 6 |
| **16** | 89 ± 4 | 36 ± 2 |

In further experiments, investigated compounds: **4**, **5**, **8a-c**, **13**, **14,** **15** and **16** were tested for their antiproliferative activity with the use of HeLa (cervical cancer) and Hek293 (human embryonic kidney) cells lines (Figure 2).

****

**Fig 2.** Cytotoxic properties of 2’-amino and 2’-azidonucleosides against HeLa and HEK293 cell lines

Obtained results showed that compounds **8a** and **14** exhibited the strongest antiproliferative effect on HeLa and Hek293 cells. Compound **8a** showed similar cytotoxic effect on both HEK293 and HeLa cell lines (IC50 approximately 3.5mM), whereas molecule **14** exhibited toxic effect only on HeLa cells (IC50 about 1.7 mM). Other compounds did not demonstrate any significant effect on cell growth. The above results suggest that in the case of CCRF-CEM and MCF7cell lines only the cytidine derivatives **5** and **16** exhibit noticeable cytotoxic efect, and apparently the presence of cytosine ring is required for the antiproliferative effect. The modifications of the sugar ring did not alter cell viability, as both 2’-azide- and 2’-amino derivatives showed similar antiproliferative effect. As for the cell lines, CCRF-CEM cells were more susceptible to cytidine derivatives, while MCF7 cells did not exhibit significant susceptibility. In comparison to CCRF-CEM and MCF7, HeLa and HEK293 cell lines turn out to be less susceptible to the tested compounds. Because of the minor effect on HeLa and HEK293 cell survival, most of the examined 2’-modified nucleosides seems to be an unsuitable scaffold for novel anticancer drugs. However, the finding that newly synthesized compound **14** showed cytotoxic effect exclusively on cancer cell line HeLa and not on normal HEK293 is extremely interesting. Future modification of this particular compound could be a promising way to obtain more powerful anticancer substances.

2’-azido-2’-deoxy- and 2’-amino-2’-deoxy- nucleoside derivatives were evaluated for their antibacterial and antifungal (against *Candida albicans* ATCC 10231) activity. Antibacterial studies were carried out against two Gram-positive bacterial strains (*Staphylococcus aureus* ATCC 6538 and *Bacillus subtilis* ATCC 6633) and three Gram-negative bacterial strains (*Escherichia coli* ATCC 8739, *Salmonella typhimurium* ATCC 14028 and *Pseudomonas aeruginosa* ATCC 9027). The results showed that all the synthesized compounds did not exhibit antibacterial nor antifungal activity at 40 mM concentration.

**Conclusions**

A series of 10 pyrimidine nucleosides modified in 2’ position with azide or amine group was subjected to the investigation of biological activity. The tested compounds exhibit rather weak cytotoxic effect. 2’-Azido-2’-deoxycytidine and 2’-amino-2’-deoxycytidine showed antiproliferative activity against CCRF-CEM cells, while newly synthesized 2’-amino-2’-deoxythymidine exhibited cytotoxic effect exclusively towards HeLa cancer cell line, but not towards the normal HEK293 cells. The lack of inhibition of cell growth by 2’-azido-2’-deoxyuridine analogues could be attributed to the poor phosphorylation by TK1 and TK2 enzymes to appropriate monophosphates, a key determinant responsible for exhibiting the cytotoxic effect. Although, in rare cases the nucleoside derivatives did not require transformation to appropriate monophosphates, the observed biological effect is related to the non-nucleosidic mode of action (McGuigan et al. 2004). Therefore, to increase the bioavailability of synthesized compounds and to overcome the problem with the first phosphorylation step, by thymidine kinases TK1 and TK2, we are currently working on the synthesis of appropriate monophosphate pro-drugs of the obtained 2’-azido-2’-deoxynucleoside analogues, followed by investigation and comparison of cytotoxic effects of nucleosides and their 5’-monophosphate esters. These results will be published in due course.

**Acknowledgements**. The equipment used was sponsored in part by the Centre for Preclinical Research and Technology (CePT), a project co-sponsored by European Regional Development Fund and Innovative Economy, The National Cohesion Strategy of Poland. We thank to Jacek Olędzki (IBB PAS) for recording ES-MS spectra.

The authors declare that they have no competing interests.

References

Akerblom L (1985) Azidocytidine is incorporated into RNA of 3T6 mouse fibroblasts. FEBS 193:203-207. doi: 10.1016/0014-5793(85)80151-4

Bauer AW, Kirby WM, Sherris JC, Turck, M (1966) Antibiotic susceptibility testing by a standarized single disc method. Am J Clin Pathol36:493-496.

Bjursell G (1978) Effects of 2’-deoxy-2’-azidocytidine on polyoma virus DNA replication: evidence for rolling circle-type mechanism. J Virolog 26:136-142.

Bjursell G, Skoog L, Thelander L, Soderman G (1977) 2'-Deoxy-2'-azidocytidine inhibits the initiation of polyoma DNA synthesis. Proc Natl Acad Sci USA 74:5310-5313.

Bobek M, Cheng YC, Bloch A (1978) Novel arabinofuranosyl derivatives of cytosine resistant to enzymatic deamination and possessing potent antitumor activity. J Med Chem 21:597-598. doi: 10.1021/jm00205a001

Cacciamani T, Vita A, Cristalli G, Vincenzetti S, Natalini P, Ruggieri S.; Amici A, Magni G(1991)Purification of human cytidine deaminase: Molecular and enzymatic characterization and inhibition by synthetic pyrimidine analogs. Arch Biochem Biophys 290:285-292. doi 10.1016/0003-9861(91)90543-R.

Cheng YC, Derse D, Tan RS, Dutschman G, Bobek M, Schroeder A, Bloch A (1981) Biological and biochemical effects of 2’-azido-2’-deoxyarabinofuranosylcytosine on human tumor cells *in vitro*. Cancer Res 41:3144-3149.

De Clerck E, Balzarini J, Descamps J, Eckstein F (1980) Antiviral, antimetabolic and antineoplastic activities of 2’- or 3-amino or –azido-substituted deoxyribonucleosides. Biochem Pharmacol 29:1849-1851. doi: 10.1016/0006-2952(80)90149-5

El Kouni MH, Naguib FNM, Panzica RP, Otter BA, Chu SH, Gosslin G, Chu CK, Schinazi RF, Shealy YF, Goudgaon N, Ozerov AA, Ueda T, IItzsch MH (1996) Effect of modifications in the pentose moiety and conformational changes on the binding of nucleoside ligands to uridine phosphorylase from *Toxoplasma gondii*. Biochem Pharmacol 51:1687-1700. doi: 10.1016/0006-2952(96)00213-4

Eliasson R, Pontis E, Reichard P, Eckstein F (1981) Replication of polyoma DNA in nuclei isolated from azidocytidine-inhibited fibroblasts. J Biol Chem 256:9044-9050.

Gai XS, Fenlon EE, Brewer SH(2010) A sensitive multispectroscopic probe for nucleic acids. J Phys Chem B 114:7958-7966. doi: 10.1021/jp101367s

Giacca M, Borella S, Calderazzo F, Bianchi LC, D’Agaro P, Rampazzo C, Bianchi V, Reichard P (1996) Synergistic antiviral action of ribonucleotide reductase inhibitors and 3’-azido-3’-deoxythymidine on HIV type 1 infection *in vitro*. AIDS Res Human Retrovirus 12:667-682. doi: 10.1089/aid.1996.12.677

Giacca M, Borella S, Calderazzo F, Ferraro P; Bianchi LC, Reichard P (1994) Inhibition of ribonucleotide reductase by 2’-substituted deoxycytidine analogues: possible application in AIDS treatment. Proc Natl Acad Sci USA 91:8403-8407.

Gold L, Pieken W, Tasset D, Janjic N, Kirschenheuter GP, Polisky B, Jayasena S, Biesecker, G, Smith D, Jenison RD, PCT Int. Appl. (1995), WO 9507364 A1 1995.03.16.

Hari Y, Akabane M, Hatanaka Y, Nakahara M, Obika S(2011) A 4-[(3*R*,4*R*)-dihydroxypyrrolidino]pyrimidin-2-one nucleobase for a CG base pair in triplex DNA. Chem Commun 47**:**4424-4426. doi: 10.1039/C1CC10138B

Iwata K, Ayusawa D, Seno T (1979) Isolation of 2’-deoxy-2’-azidocytidine-resistant mutants deficient in deoxycytidine kinase in mouse FM3A cells. Cell Struct Funct 4:317-320. doi: 10.1247/csf.4.317

Kierdaszuk B, Krawiec K, Kazimierczuk Z, Jacobsson U, Johansson NG, Munch-Petersen B, Eriksson S, Shugar D (1998) Substrate/inhibitor specificities of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) in: Griesmacher *el al.* eds.Purine and Pyrimidine Metabolism in Man IX. New York: Plenum Press; 623-627.

Kierdaszuk B, Krawiec K, Kazimierczuk Z, Jacobsson U, Johansson NG, Munch-Petersen B, Eriksson S, Shugar D (1999) Substrate/inhibitor properties of human deoxycytidine kinase (dCK) and thymidine kinases (TK1 and TK2) towards the sugar moiety of nucleosides, including O’-alkyl analogues. Nucleosid. Nucleotid. Nucleic Acids 18:1883-1903. doi:10.1080/07328319908044850

Kirschenheuter GP, Zhai Y, Pieken WA(1994) An improved synthesis of 2’-azido-2’-deoxyuridine. Tetrahedron Lett 35:8517-8520. doi: 10.1016/S0040-4039(00)78425-5.

Kobayashi Y, Yamamoto K, Sai T, Nakano M, Kumadaki I(1980) Studies on organic fluorine compounds. Part 35. Trifluoromethylation of pyrimidine- and purine-nucleosides with trifluoromethyl-copper complex. J Chem Soc Perkin Trans 1 2755-2761. doi: 10.1039/P19800002755

Kumaki Y, Day CW, Smee DF, Morrey JD, Barnard DL (2011) *In vitro* and *in vivo* efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antivir Res 92:329-340. doi: 10.1016/j.antiviral.2011.09.001

Matsuda A, Yasuoka J, Sasaki T, Ueda T (1991) Nucleosides and nucleotides. 95. Improved synthesis of 1-(2-azido-2-deoxy-β-D-arabinofuranosyl)cytosine (Cytarazid) and –thymine. Inhibitory spectrum of Cytarazid on the growth of various human tumor cells in vitro. J Med Chem 34:999-1002. doi: 10.1021/jm00107a018

McGuigan C, Pathirana RN, Snoeck R, Andrei G, De Clercq E, Balzarini J (2004) Discovery of a New Family of Inhibitors of Human Cytomegalovirus (HCMV) Based upon Lipophilic Alkyl Furano Pyrimidine Dideoxy Nucleosides: Action via a Novel Non-Nucleosidic Mechanism. J Med Chem 47:1847-1851. doi: 10.1021/jm030857h

Mieczkowski A, Bazlekova M, Bagiński M, Wójcik J, Winczura A, Miazga A, Ghahe SS, Gajda R, Woźniak K, Tudek B(2016) A mild and efficient approach to the 6*H*-oxazolo[3,2-*f*]pyrimidine-5,7-dione scaffold *via* unexpected rearragement of 2,3-dihydropyrimido[6,1-*b*][1,5,3]dioxazepine-7,9(5*H*,8*H*)-diones: synthesis, crystallographic studies and cytotoxic activity screening. Tetrahedron Lett. 57:743-746. doi: 10.1016/j.tetlet.2016.01.006

Mieczkowski A, Makowska M, Sekula J, Tomczyk E, Zalewska E, Nasulewicz-Goldeman A, Wietrzyk J(2015) Bicyclic cytarabine analogues: synthesis and investigation of antitumor properties of novel, 6-aryl and 6-alkyl-3*H*-pyrrolo[2,3*-d*]pyrimidin-2(7*H*)-one arabinosides. Tetrahedron 71:8454-8461. doi: 10.1016/j.tet.2015.09.015

Mieczkowski A, Tomczyk E, Makowska M, Nasulewicz-Goldeman A, Gajda R, Woźniak K, Wietrzyk J(2016) Synthesis and investigation of antitumor properties of novel bicyclic furopyrimidine, pyrrolopyrimidine and pyrimidopyridazine nucleoside analogues. Synthesis 48:566-572. doi: 10.1055/s-0035-1561277

Mitsuya H, Reinhold KJ, Furman PA, St Clair, MH, Lehrman SN, Gallo RC, Bolognesi D, Barry DW, Broder S (1985) 3’-Azido-3’-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci U.S.A. 82:7096-7100.

Pathak, P (2002) Azidonucleosides: Synthesis, Reactions, and Biological Properties. Chem Rev 102:1623-1667. doi: 10.1021/cr0104532

Pokrovskii, AG, Il'icheva TN, Belanov EF, Volkov GN, Kukhanova MK, Aleksandrova LA. Russ. (2005), RU 2264409 C2, 2005.11.20.

Reichard P, Rowen L, Eiiassoh J, Hobbs J, Eckstein F (1978) Inhibition of primase, the dnaG protein of *Escherichia coli* by 2’-deoxy-2’-azidocytidine triphosphate. J Biol Chem 253:7011-7016.

Roy B, Verri A, Lossani A, Spadari S, Focher F, Aubertin AM, Gosselin G, Mathe C, Perigaud C (2004) Enantioselectivity of ribonucleotide reductase: a first study using stereoisomers of pyrimidine 2’-azido-2’-deoxynucleosides. Biochem Pharmacol 68:711-719. doi: 10.1016/j.bcp.2004.05.002

Smith DB, Martin JA, Klumpp K, Baker SJ, Blomgren PA, Devos R.; Granycome C, Hang J, Hobbs CJ, Jiang WR, Laxton C.; Le Pogam S, Leveque V, Ma H, Maile G, Merret JH, Pichota A, Sarma K, Smith M, Swallow S, Symons J, Vesey D, Najera I, Cammack N (2007) Design, synthesis, and antiviral properties of 4’-substituted ribonucleosides as inhibitors of hepatitis C virus replication: The discovery of R1479. Bioorg Med Chem Lett 17:2570-2576.

doi: 10.1016/j.bmcl.2007.02.004

Torrence PF, Bobst AM, Waters JA, Witkop B(1973)Synthesis and characterization of potential interferon inducers. Poly(2’-azido-2’-deoxyuridylic acid). Biochemistry 12:3962-3972. doi: 10.1021/bi00744a028

Torrence PF, Waters JA, Buckler CE, Witkop B(1973) Effect of pyrimidine and ribose modifications on the antiviral activity of synthetic polynucleotides. Biochem Biophys Res Commun 52:890-898. doi: 10.1016/0006-291X(73)91021-8.

Wanf J, Neuhard J, Eriksson S (1998) An *Escherichia coli* system expressing human deoxyribonucleoside salvage enzymes for evaluation of potential antiproliferative nucleoside analogs. Antimicrob Agents Chemother 42:2620-2625.

Wnuk SF, Chowdhury SM, Garcia PI Jr, Robins MJ (2002) Stereodefined synthesis of O3’-labeled uracil nucleosides, 3’-[17O]-2’-azido-2’-deoxyuridine 5’-diphosphate as a probe for the mechanism of inactivation of ribonucleotide reductase. J Org Chem 67:116-119. doi: 10.1021/jo010899i

Vickers MF, Zhang J, Visser F, Tackaberry T, Robins MJ, Nielsen LPC, Nowak I, Baldwin SA, Young JD, Cass CE (2004) Uridine recognition motifs of human equilibrative nucleoside transporters 1 and 2 produced in *Sacharomycetes cerevisiae*. Nucleosid. Nucleotid. Nucleic Acids 23:361-373. doi: 10.1081/NCN-120028333

Zhang J, Smith KM, Tackaberry T, Visser F, Robins MJ, Nielsen LPC, Nowak I, Karpinski E, Baldwin SA, Young JD, Cass CE (2005) Uridine binding and transportability determinants of human concentrative nucleoside transporters. Mol Pharmacol 68:830-839. doi: 10.1124/mol.105.012187

Zhang J, Visser F, Vickers MF, Lang T, Robins MJ, Nielsen LPC, Nowak I, Baldwin SA, Young JD, Cass CE (2003) Uridine binding motifs of human concentrative nucleoside transporters 1 and 3 produced in *Sacharomycetes cerevisiae*. Mol Pharmacol 64:1512-1520. doi: 10.1124/mol.64.6.1512